全文获取类型
收费全文 | 13892篇 |
免费 | 1431篇 |
国内免费 | 134篇 |
专业分类
耳鼻咽喉 | 195篇 |
儿科学 | 407篇 |
妇产科学 | 321篇 |
基础医学 | 1831篇 |
口腔科学 | 430篇 |
临床医学 | 1581篇 |
内科学 | 2603篇 |
皮肤病学 | 139篇 |
神经病学 | 1107篇 |
特种医学 | 548篇 |
外国民族医学 | 1篇 |
外科学 | 2192篇 |
综合类 | 368篇 |
一般理论 | 19篇 |
预防医学 | 1474篇 |
眼科学 | 352篇 |
药学 | 999篇 |
中国医学 | 18篇 |
肿瘤学 | 872篇 |
出版年
2021年 | 177篇 |
2020年 | 132篇 |
2019年 | 219篇 |
2018年 | 257篇 |
2017年 | 211篇 |
2016年 | 207篇 |
2015年 | 256篇 |
2014年 | 307篇 |
2013年 | 499篇 |
2012年 | 626篇 |
2011年 | 640篇 |
2010年 | 427篇 |
2009年 | 388篇 |
2008年 | 599篇 |
2007年 | 685篇 |
2006年 | 589篇 |
2005年 | 600篇 |
2004年 | 619篇 |
2003年 | 605篇 |
2002年 | 553篇 |
2001年 | 396篇 |
2000年 | 405篇 |
1999年 | 368篇 |
1998年 | 199篇 |
1997年 | 194篇 |
1996年 | 148篇 |
1995年 | 142篇 |
1994年 | 123篇 |
1993年 | 137篇 |
1992年 | 259篇 |
1991年 | 258篇 |
1990年 | 277篇 |
1989年 | 251篇 |
1988年 | 238篇 |
1987年 | 185篇 |
1986年 | 235篇 |
1985年 | 196篇 |
1984年 | 164篇 |
1983年 | 167篇 |
1982年 | 128篇 |
1981年 | 118篇 |
1980年 | 139篇 |
1979年 | 164篇 |
1978年 | 144篇 |
1977年 | 141篇 |
1976年 | 115篇 |
1975年 | 140篇 |
1974年 | 144篇 |
1973年 | 146篇 |
1972年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
3.
4.
5.
SH Lee† CP Choi‡ HC Eun† OS Kwon† 《Journal of the European Academy of Dermatology and Venereology》2006,20(7):860-863
BACKGROUND: On December 26, 2004, the biggest earthquake for 40 years, measuring 9.0 on the Richter scale, triggered a tsunami that pounded the coastal areas of South Asia and East Africa. The effects of the tsunami on skin conditions have not been evaluated. OBJECTIVE: To determine the influence of the tsunami on skin conditions by evaluating the skin problems of patients presenting at hospitals after the tsunami. METHODS: Between 5 and 25 January 2005, two dermatologists evaluated patients who complained of skin problems at an outpatient clinic and emergency room of a general hospital in Banda Aceh, Aceh Province, Indonesia. RESULTS: The total number of patients that presented during the study period was 235 (131 males and 104 females), and they had a total of 265 skin problems. In terms of age distribution, most subjects were in their fourth decade (23.0%), followed by the third (22.6%) and fifth decade (16.6%). The most prevalent skin problems were infections-infestations (32.5%), followed by eczemas (29.8%) and traumatic skin disorders (29.4%). In males, traumatic skin disorders were most common. The great majority of infection-infestation cases involved superficial fungal infections. Contact dermatitis accounted for three-quarters of eczema cases, and mainly involved the arms (40.0%) and legs (27.1%). The majority of traumatic skin disorders were lacerations, punctures and penetrations, and the feet (44.7%) and hands (18.8%) were most frequently affected. CONCLUSIONS: Unhygienic conditions, exposure to a hazardous environment and contact with various objects during and after the tsunami probably increased the prevalence of infections-infestations, traumatic skin disorders and contact dermatitis. To prevent these problems and associated secondary bacterial infections, health-related education and early medical management are required. 相似文献
6.
7.
8.
9.
Summary— KR31080 (2-butyl-5-methyl-6-(1-oxopyridin-2-yl)-3-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-3H-imidazo[4,5-b] pyridine) is a potent inhibitor of angiotensin type 1 (AT1 ) receptors in rabbit aorta and human recombinant AT1 receptors. In the isolated rabbit thoracic aorta, KR31080 caused a nonparallel shift to the right of the concentration-response curves to angiotensin II (All) with decreased maximal response (pD'2 = 10.1 ± 0.1), but had no effect on the contractile response induced by norepinephrine. KR31080 inhibited specific [125 I]AII binding to rabbit aortic membranes (AT, receptors) and [125 I][Sar1 , Ile8 ]AII binding to human recombinant AT1 receptors in a concentration-dependent manner with IC50 values of 0.84 ± 0.08 nM and 1.92 ± 0.15 nM, respectively, but did not inhibit specific [125 I)AII binding to bovine cerebellum membranes (ÀT2 receptors). In the Scatchard analysis, KR31080 interacted with rabbit aortic AT1 receptors in a competitive manner, similar to losartan. These results demonstrate that KR31080 is a potent and AT1 selective angiotensin receptor antagonist which exerts a competitive antagonism in the [125 I]AII binding assay and insurmountable AT1 receptor antagonism in the functional study. 相似文献
10.